Loading...

BCDA BIOCARDIA INC US FDA Inspections 8-K Filing

BCRD

BCD

BIOCARDIA INC

(BCDA)

2025 8-K

Financial Results Announcement

FDA Pathway Update

Patent Approval Announcement

Positive Consultation Outcome

Delisting Notice

FDA Submission Update

Financial Results Update

FDA Approval Update

Clinical Trial Results

FDA Approval Update

Clinical Data Announcement

Clinical Consultation Update

Financial Results Announcement

Clinical Trial Announcement

Trial Enrollment Announcement

Annual Meeting Notice

Compliance Regained

Compliance Update

Positive Meeting Outcomes

Stock Offering Details

Stock Offering Announcement

CardiAMP Results Update

New Partnership Agreement

Product Expansion

Clinical Trials

Geographic Expansion

Equity Offerings

Other Special Situation

Financial Statements

New Product Launches

Clinical Trials

Equity Offerings

Trial Enrollment

Nasdaq Compliance

Conference Call

Clinical Trial Results

Financial Results

Trial Enrollment Complete

Conference Presentation

Regulatory Update

Financial Results

Clinical Trial Update

Nasdaq Compliance

Public Offering

Public Offering

Financial Results

Patent Issuance

Collaborative Phase II Tria...

Patent Issuance

Reverse Stock Split

Annual Meeting and Reverse ...

Financial Results Announcement

Financial Results Announcement

Partnership Announcement

Other Special Situation

Announcement of Positive In...

Private Placement

Announcement of Scientific ...

At The Market Offering Agre...

Update on Stockholder Advis...

Extension of Proposal Deadline

Update on CardiAMP autologo...

Securities Purchase Agreement

FDA Approval for Phase III ...

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Product Updates

Market Expansion

Termination of Agreement an...

Securities Purchase Agreement

Suspension of Sales

FDA Review Completion for C...

Financial Results Announcement

Patent Issuance

Amended Bylaws Approval

Announcement of Presentations

Patent Issuance

External Links:

On December 16, 2025, BioCardia, Inc. announced the completion of its third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency for the CardiAMP Cell Therapy aimed at treating Heart Failure with Reduced Ejection Fraction, allowing advancement to a formal clinical consultation pending safety and efficacy approval.

AI Assistant

BIOCARDIA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.